Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the publication of results from the LEMTRADA™ (alemtuzumab) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis (MS) in the November 1, 2012, online issue of The Lancet.
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine.
Sanofi and its subsidiary Genzyme announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new data from Genzyme’s clinical development programs for AUBAGIO® (teriflunomide) and LEMTRADA TM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).
Paris, France – October 5, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results from the landmark ORIGIN trial showing treatment with Lantus® was approximately 3-fold more likely to achieve and maintain target glycemic levels, defined as HbA1C < 6.5% in this analysis, vs. standard care in individuals with pre-diabetes or early type 2 diabetes at high cardiovascular risk.
Sanofi Diabetes is funding “Start Right, Eat Right”, a public nutrition initiative taking place in Berlin, Germany, October 2nd - October 5th 2012. This event coincides with the 48th Annual Meeting of the European Association of the Study of Diabetes (EASD).
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has signed an agreement to acquire Genfar S.A., a leading pharmaceuticals manufacturer headquartered in Bogota, Colombia. With this acquisition, Sanofi will become a market leader in Colombia and expand its portfolio of affordable pharmaceuticals in Latin America.
Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.
Paris, France - October 2, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that ENGAGE, the first Phase 3 trial of its investigational oral therapy, eliglustat tartrate, in previously untreated patients with Gaucher disease type 1, met its primary endpoint.
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced results from a study showing that the mechanism of action of once-daily Lyxumia® (lixisenatide) significantly delayed gastric emptying, a process accompanied by significant post-prandial glucose (PPG) lowering.
Sanofi (EURONEXT: SAN and NYSE: SNY) and the Global Alliance for TB Drug Development (TB Alliance) announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide1 in 2010.
Paris, France – September 12, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO® (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).
Stockholm – 3 september 2012 – Sanofi meddelar idag att Anna-Kaija Grönblad efterträder Laurent Dousset som vd för Sanofi Sverige. Hon kommer samtidigt att bli divisionschef för onkologi i Norden och Baltikum. Laurent Dousset går vidare till en ny position på huvudkontoret i Paris.
Paris, France - August 27, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced that Genzyme has received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of LEMTRADA™ (alemtuzumab) as a treatment for relapsing multiple sclerosis.
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.
Sanofi (EURONEXT: SAN and NYSE: SNY) and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, today announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass.
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it was granted the award for “Leading Pan-European Quoted Company for Investor Relations” in the 2012 Thomson Reuters Extel Survey. Considered the leading benchmark for excellence in Investor Relations (IR), the survey highlights achievement across companies listed in Europe.
Den internationella studien ORIGIN (Outcome Reduction with Initial Glargine Intervention) har undersökt om det går att förhindra eller skjuta upp kardiovaskulära händelser som kan följa av typ 2-diabetes och om man kan förhindra utvecklingen av typ 2-diabetes hos personer som riskera få denna sjukdom, genom att behandla med Lantus® (insulin glargin) på ett tidigare stadium än vad som görs idag.
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA™ (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS).